Inflammatory Bowel Disease: Perioperative Pharmacological Considerations

August 2011
Mayo Clinic Proceedings;Aug2011, Vol. 86 Issue 8, p748
Academic Journal
The perioperative management of patients with inflammatory bowel disease is challenging given the altered immune system that results from a variety of biologic and immunomodulator therapies. Clinicians are often faced with challenges and complicated equations when deciding on the type and dose of medication. To understand the effect of these medications and review the evidence regarding the management of these medications in the perioperative setting, a PubMed-based literature search (January 1, 1960, through April 1, 2011) was conducted using the following search terms: perioperative management, risk, outcome, inflammatory bowel disease, ulcerative colitis, Crohn's disease, aminosalicylates, glucocorticoids, purine analogues, cyclosporine, methotrexate, biologic therapy, infliximab, and thromboembolism. The 414 articles identified were manually sorted to exclude those that did not address perioperative risk, outcomes, and medications In the abstracts, yielding 84 articles for review. Additional references were obtained from the citations within the retrieved articles. This review surveys the findings of the selected articles and presents guidelines and resources for perioperative medication management for patients with inflammatory bowel disease undergoing surgery.


Related Articles

  • How do patients with inflammatory bowel disease want their biological therapy administered? Allen, Patrick B.; Lindsay, Hannah; Tham, Tony C. K. // BMC Gastroenterology;2010, Vol. 10, p1 

    Background: Infliximab is usually administered by two monthly intravenous (iv) infusions, therefore requiring visits to hospital. Adalimumab is administered by self subcutaneous (sc) injections every other week. Both of these anti-TNF drugs appear to be equally efficacious in the treatment of...

  • The use of oral topically acting glucocorticosteroids in the treatment of inflammatory bowel disease. Rutgeerts, P. // Mediators of Inflammation;Jun98, Vol. 7 Issue 3, p137 

    GLUCOCORTICOSTEROIDS are the mainstay of treatment of active Crohn's disease and ulcerative colitis. These drugs however carry important cosmetic short-term side effects and when used long-term they induce severe irreversible complications. Topically acting glucocorticosteroids, especially...

  • Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Rutgeerts, Paul; Vermeire, Severine; Van Assche, Gert // Gut;Apr2007, Vol. 56 Issue 4, p453 

    The main goal of treatment for Crohn's disease and ulcerative colitis has always been the induction and maintenance of symptomatic improvement or at best remission. It has been shown by many studies that the long-term outcome of these diseases is not influenced by standard treatments and that...

  • Consumption of Dental Treatment in Patients with Inflammatory Bowel Disease, a Register Study. Johannsen, Annsofi; Fored, Michael C.; Håkansson, Jan; Ekbom, Anders; Gustafsson, Anders // PLoS ONE;8/12/2015, Vol. 10 Issue 8, p1 

    Objective: The aim of this study was to compare the consumption of dental treatment among patients with Crohn´s disease (CD) or ulcerative colitis (UC) compared to age and gender matched control groups. Design: The study group comprised 2085 patients with CD and 3161 with UC from the...

  • Factors in the management of Crohn's disease: a discussion paper. Cooke, W. T. // Journal of the Royal Society of Medicine;Oct1981, Vol. 74 Issue 10, p753 

    The article provides an overview of the factors that influenced the management and therapeutic interpretation of Crohn's disease. These involve the importance of measuring the disease activity, mortality rates, surgical involvement and medical therapy. However, surgical resection is still...

  • Medical management of Crohn's disease. Cummings, J.R. Fraser; Keshav, Satish; Travis, Simon P.L. // BMJ: British Medical Journal (International Edition);5/10/2008, Vol. 336 Issue 7652, p1062 

    The article presents an overview of the medical management of Crohn's disease, which is a chronic, relapsing and remitting inflammatory condition of the gastrointestinal tract. A discussion of the worldwide prevalence of the disease, its symptoms, and of when physicians should refer Crohn's...

  • Medical Management of Crohn's Disease in 2006: What's on the Horizon? Lichtenstein, Gary R. // American Journal of Gastroenterology;Jun2007 Supplement, Vol. 102, pS2 

    The article focuses on the treatment approach for Crohn's disease. The monoclonal antibody therapy is found to be effective due to the achievement of adequate serological levels that allow patients to tolerate the biologic therapy without harmful effects. Part of such approach is the integration...

  • Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Hanauer, Stephen B. // Gut;Sep2007, Vol. 56 Issue 9, p1181 

    Since the introduction of infliximab to treat Crohn's disease, combination therapy, with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.

  • A Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease. Feagan, Brian G.; Fedorak, Richard N.; Irvine, E. Jan; Wild, Gary; Sutherland, Lloyd; Steinhart, A. Hillary; Greenberg, Gordon R.; Koval, John; Wong, Cindy J.; Hopkins, Marybeth; Hanauer, Stephen B.; McDonald, John W.D. // New England Journal of Medicine;06/01/2000, Vol. 342 Issue 22, p1627 

    Background: Patients with Crohn's disease often have relapses. Better treatments are needed for the maintenance of remission. Although methotrexate is an effective short-term treatment for Crohn's disease, its role in maintaining remissions is not known. Methods: We conducted a double-blind,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics